Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 926874, 4 pages
http://dx.doi.org/10.1155/2015/926874
Case Report

Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A

1Department of Hematology, Tenshi Hospital, Kita-12, Higashi-3-1-1, Higashi-ku, Sapporo 065-0012, Japan
2Department of Gastroenterology, Tenshi Hospital, Kita-12, Higashi-3-1-1, Higashi-ku, Sapporo 065-0012, Japan

Received 10 July 2015; Accepted 25 August 2015

Academic Editor: Ramon Tiu

Copyright © 2015 Tohru Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. S. Young, R. T. Calado, and P. Scheinberg, “Current concepts in the pathophysiology and treatment of aplastic anemia,” Blood, vol. 108, no. 8, pp. 2509–2519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. J. van Esser, B. van der Holt, E. Meijer et al., “Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT,” Blood, vol. 98, no. 4, pp. 972–978, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Scheinberg, S. H. Fischer, L. Li et al., “Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia,” Blood, vol. 109, no. 8, pp. 3219–3224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Raghavachar, A. Ganser, M. Freund, H. Heimpel, F. Herrmann, and H. Schrezenmeier, “Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia,” Cytokines and Molecular Therapy, vol. 2, no. 2, pp. 215–223, 1996. View at Google Scholar · View at Scopus
  5. E. Calistri, M. Tiribelli, M. Battista et al., “Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia,” American Journal of Hematology, vol. 81, no. 5, pp. 355–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Wondergem, S. J. C. Stevens, J. J. W. M. Janssen et al., “Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression,” Blood, vol. 111, no. 3, article 1739, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. M. Viola, Y. Zu, K. R. Baker, and S. Aslam, “Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy,” Medical Oncology, vol. 28, no. 4, pp. 1604–1608, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Sugimoto-Sekiguchi, H. Tashiro, R. Shirasaki et al., “Colonic EBV-associated lymphoproliferative disorder in a patient treated with rabbit antithymocyte globulin for aplastic anemia,” Case Reports in Gastrointestinal Medicine, vol. 2012, Article ID 395801, 6 pages, 2012. View at Publisher · View at Google Scholar
  9. K. Ohata, N. Iwaki, T. Kotani, Y. Kondo, H. Yamazaki, and S. Nakao, “An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia,” Acta Haematologica, vol. 127, no. 2, pp. 96–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Nakanishi, M. Ishida, K. Hodohara et al., “Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 4, pp. 1748–1756, 2014. View at Google Scholar · View at Scopus
  11. S. H. Swerdlow, S. A. Webber, A. Chadburn, and J. A. Ferry, “Post-transplant lymphoproliferative disorders,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., pp. 343–349, IARC Press, Lyon, France, 2008. View at Google Scholar
  12. P. Scheinberg, O. Nunez, B. Weinstein et al., “Horse versus rabbit antithymocyte globulin in acquired aplastic anemia,” The New England Journal of Medicine, vol. 365, no. 5, pp. 430–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. E. H. Atta, D. S. P. Dias, V. L. N. Marra, and A. M. de Azevedo, “Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study,” Annals of Hematology, vol. 89, no. 9, pp. 851–859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H.-J. Wagner, Y. C. Cheng, M. H. Huls et al., “Prompt versus preemptive intervention for EBV lymphoproliferative disease,” Blood, vol. 103, no. 10, pp. 3979–3981, 2004. View at Publisher · View at Google Scholar · View at Scopus